Literature DB >> 23490994

The bone marrow microenvironment in Waldenström macroglobulinemia.

Amit Agarwal1, Irene M Ghobrial.   

Abstract

Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma characterized by widespread involvement of the bone marrow (BM). The BM microenvironment serves as not only a site for disease involvement, but it also appears that the interaction of WM cells with the BM is essential for the pathogenesis of WM. The BM microenvironment consists of the cellular and noncellular compartments. The BM has been shown to regulate cell proliferation, cell cycle, and drug resistance as well as cell dissemination and cell trafficking of WM cells. A better understanding of the role of the BM microenvironment in the pathogenesis of WM can help guide better therapeutic strategies that can target the tumor clone and also regulate the BM microenvironment.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23490994      PMCID: PMC3654400          DOI: 10.1016/j.clml.2013.02.006

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  25 in total

1.  Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.

Authors:  O Tournilhac; D D Santos; L Xu; J Kutok; Y-T Tai; S Le Gouill; L Catley; Z Hunter; A R Branagan; J A Boyce; N Munshi; K C Anderson; S P Treon
Journal:  Ann Oncol       Date:  2006-06-20       Impact factor: 32.976

Review 2.  The stem cell niches in bone.

Authors:  Tong Yin; Linheng Li
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

3.  B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.

Authors:  Sherine F Elsawa; Anne J Novak; Deanna M Grote; Steven C Ziesmer; Thomas E Witzig; Robert A Kyle; Stacey R Dillon; Brandon Harder; Jane A Gross; Stephen M Ansell
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

4.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

5.  Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia.

Authors:  Evangelos Terpos; Athanasios Anagnostopoulos; Efstathios Kastritis; Aristotelis Bamias; Konstantinos Tsionos; Meletios-Athanassios Dimopoulos
Journal:  Br J Haematol       Date:  2006-05       Impact factor: 6.998

Review 6.  Integrin-mediated drug resistance in multiple myeloma.

Authors:  J S Damiano; W S Dalton
Journal:  Leuk Lymphoma       Date:  2000-06

Review 7.  How do stem cells find their way home?

Authors:  Tsvee Lapidot; Ayelet Dar; Orit Kollet
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

8.  Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood.

Authors:  Jitra Kriangkum; Brian J Taylor; Steven P Treon; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

9.  Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions.

Authors:  Roelandt F J Schop; W Michael Kuehl; Scott A Van Wier; Gregory J Ahmann; Tammy Price-Troska; Richard J Bailey; Syed M Jalal; Ying Qi; Robert A Kyle; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

Review 10.  Waldenström macroglobulinaemia.

Authors:  Irene M Ghobrial; Morie A Gertz; Rafael Fonseca
Journal:  Lancet Oncol       Date:  2003-11       Impact factor: 41.316

View more
  6 in total

1.  PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.

Authors:  Mona Sobhani; Jahangir Abdi; Saha N Manujendra; Christine Chen; Hong Chang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.

Authors:  Shahrzad Jalali; Tammy Price-Troska; Jonas Paludo; Jose Villasboas; Hyo-Jin Kim; Zhi-Zhang Yang; Anne J Novak; Stephen M Ansell
Journal:  Blood Adv       Date:  2018-08-14

3.  Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.

Authors:  Stephan J Matissek; Weiguo Han; Mona Karbalivand; Mohamed Sayed; Brendan M Reilly; Shayna Mallat; Shimaa M Ghazal; Manit Munshi; Guang Yang; Steven P Treon; Sarah R Walker; Sherine F Elsawa
Journal:  Epigenomics       Date:  2020-12-24       Impact factor: 4.778

4.  Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.

Authors:  Ari Ahn; Chan Jeoung Park; Young Uk Cho; Seongsoo Jang; Eul Ju Seo; Jung Hee Lee; Dok Hyun Yoon; Cheolwon Suh
Journal:  Ann Lab Med       Date:  2020-05       Impact factor: 3.464

Review 5.  Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies.

Authors:  Ava J Boutilier; Lina Huang; Sherine F Elsawa
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

Review 6.  Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Authors:  Siegfried Janz
Journal:  ISRN Hematol       Date:  2013-09-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.